Drug intelligence / Profile preview

AD-227A + AD-227B

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-227A + AD-227B is an oral fixed-dose combination of two small molecule drugs under development for the treatment of essential hypertension. The combination is being evaluated in phase 3 clinical trials to assess its efficacy and safety in patients with high blood pressure. Both components, AD-227A and AD-227B, are developed by Addpharma and are intended to be administered together as a single daily tablet. The precise mechanisms of action and molecular targets for each component have not been publicly disclosed as of June 2025[1][2][6][7][9][10].

Beyond the preview

Go deeper on AD-227A + AD-227B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-227A + AD-227B.

Explore the full profile